| Nov 20, 2009 | 11:31 | Emerging Stock Report Initiates Independent Research Coverage on Inovio Biomed Corp |
| Emerging Stock Report, a leading provider of sector specific independent investment research, today initiated coverage on Inovio Biomed Corp (NYSE Amex:INO). Emerging Stock Report is currently offering a complimentary trial subscription to the investment community.
continued... |
|
| Nov 20, 2009 | 09:00 | Experienced Biotech and Regulatory Expert Becomes Formal Member of the biOasis Team |
| biOasis Technologies Inc. (TSX-V:BTI) is pleased to announce that Dr. Delara Karkan has been named as Senior Industry Scientific Advisor.
continued... |
|
| Nov 19, 2009 | 16:09 | XOMA Receives NASDAQ Determination Letter |
 | XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that it received a letter from the staff of The NASDAQ Stock Market LLC on November 13, 2009 indicating that the NASDAQ staff has concluded that XOMA's previously-announced common share financing completed on September 30, 2009 did not comply with NASDAQ's Listing Rule 5635(d)(2). Listing Rule 5635(d)(2) requires that a company obtain shareholder approval for the issuance of common shares or securities exercisable for common shares equal to 20% or more of the common shares outstanding before the issuance for less than the greater of book or market value of the shares. Receipt of this letter has no effect on the current listing status of the common shares.
continued... |
|
| Nov 19, 2009 | 07:00 | IRIS International to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 |
 | IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that Chairman, President and Chief Executive Officer Cesar Garcia will present an overview of the Company at the 21st Annual Piper Jaffray Health Care Conference on Tuesday, December 1, 2009 at 2:30 p.m. Eastern time at the New York Palace Hotel in New York City.
continued... |
|
| Nov 19, 2009 | 06:50 | Trading Overview for Sinobiopharma Inc. Issued by StockPreacher.com |
| StockPreacher.com announces an investment report featuring biotechnology company Sinobiopharma Inc. (OTCBB:SNBP). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
continued... |
|
| Nov 19, 2009 | 06:50 | Beacon Equity Issues Technical Trading Overview for Questcor Pharmaceuticals Inc. |
| BeaconEquity.com announces an investment report featuring Questcor Pharmaceuticals Inc. (Nasdaq:QCOR). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
continued... |
|
| Nov 19, 2009 | 06:00 | OraSure Technologies Announces Settlement of Patent Infringement Lawsuit With Inverness and Church & Dwight |
 | OraSure Technologies, Inc. (Nasdaq:OSUR) today announced the settlement of the patent infringement lawsuit filed against OraSure by Inverness Medical Innovations, Inc. (NYSE:IMA), Inverness Medical Switzerland GmbH and Church & Dwight, Co., Inc. (NYSE:CHD).
continued... |
|
| Nov 18, 2009 | 11:21 | Pressure BioSciences, Inc. Announces the Receipt of Over $1.1 Million From the Initial Tranche of a Private Placement |
| Pressure BioSciences, Inc. (Nasdaq:PBIO) ("PBI" or the "Company") today announced that it has closed on the sale of approximately $1.16 million of units in the first tranche of a $2.5 million private placement. Each unit was priced at $18.80 and consists of (i) one share of non-voting Series B Convertible Preferred Stock, and (ii) one warrant to purchase a share of Series B Convertible Preferred Stock at an exercise price of $23.80 per share, expiring on August 11, 2011. Each share of non-voting Series B Convertible Preferred Stock is convertible into ten shares of the Company's common stock. The closing bid of PBI common stock as reported on the NASDAQ Capital Market as of the close of business on Tuesday, November 17, 2009 was $1.43 per common share.
continued... |
|
| Nov 18, 2009 | 08:45 | Threshold Pharmaceuticals Presents Interim Prostate Cancer Data From Early Stage Trials of TH-302 |
| Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented yesterday at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held November 15 to 19, 2009, in Boston, MA.
continued... |
|
| Nov 18, 2009 | 06:50 | StockPreacher.com Issues Trading Outlook for Arena Pharmaceuticals Inc. |
| StockPreacher.com announces an investment report featuring biopharmaceutical company Arena Pharmaceuticals Inc. (Nasdaq:ARNA). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
continued... |
|
| Nov 18, 2009 | 02:05 | Evotec Wins German Government Research Grant |
| Evotec (Frankfurt:EVT) (TecDAX), a leading provider in the discovery and development of novel small molecule drugs, today announced that it has been granted up to EUR 2.5 m in research funds from the BMBF, within the Neu2 consortium, to advance research and development activities on the target Serine Racemase for potential use in neuroprotection. Evotec will use its drug discovery platform and expertise in progressing this program towards the clinic, particularly making use of its high quality compound library and proprietary fragment-based drug discovery platform.
continued... |
|
| Nov 17, 2009 | 16:00 | Achillion Receives Notice From NASDAQ |
| Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported that it received notification from the NASDAQ Listings Qualification Department that the Company's stockholders' equity of $7,214,000, as reported in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2009 that it filed with the Securities and Exchange Commission, does not comply with the minimum stockholders' equity requirement of $10,000,000 for continued listing on The NASDAQ Global Market pursuant to NASDAQ Listing Rule 5450(b)(1)(A).
continued... |
|
| Nov 17, 2009 | 15:47 | Capstone Therapeutics Announces Transfer to Nasdaq Capital Market |
 | Capstone Therapeutics (the "Company") (Nasdaq:CAPS) today announced that its application to transfer the listing of its common stock from The Nasdaq Global Market to The Nasdaq Capital Market has been approved by Nasdaq. This transfer will be effective at the opening of business on Friday, November 20, 2009, and the Company's common stock will continue to trade under the symbol "CAPS." The Nasdaq Capital Market is a continuous trading market that operates in substantially the same manner as The Nasdaq Global Market. All companies listed on The Nasdaq Capital Market must meet certain financial requirements and comply with Nasdaq's corporate governance requirements.
continued... |
|
| Nov 17, 2009 | 12:30 | OXiGENE Reports Positive Safety Data From Phase 2 Trial of ZYBRESTAT in Non-Small Cell Lung Cancer at the 2009 AACR-NCI-EORTC Conference |
 | OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today reported positive interim safety data from the FALCON (Fosbretabulin in Advanced Lung Oncology) study, a Phase 2, randomized, controlled study of ZYBRESTAT (fosbretabulin) in patients with advanced non-small cell lung cancer (NSCLC). The data from this planned interim safety analysis indicated that the combination of fosbretabulin with carboplatin and paclitaxel plus bevacizumab (Avastin(R)) appeared to be well-tolerated, and that there were no significant overlapping toxicities with bevacizumab. Notably, 5 of the 6 patient deaths during the evaluation period were due to disease progression and occurred in the control arm. The data were presented in a poster by Edward Garon, M.D., Assistant Professor of Medicine at the University of California, Los Angeles, principal investigator for the Phase 2 trial, at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference. A further analysis of the efficacy and tolerability of this novel combination is expected to be presented at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO), scheduled for June 4-8, 2010 in Chicago, IL.
continued... |
|
| Nov 17, 2009 | 08:00 | XOMA Appoints Jim Neal Vice President of Business Development |
| XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced that James R. Neal has joined the company as Vice President, Business Development. Mr. Neal will oversee XOMA's business development strategy and lead the team to execute key licensing initiatives to build and support XOMA's proprietary therapeutic pipeline and biodefense programs, to market the company's antibody technologies and to assess commercial opportunities and develop product candidates commercially.
continued... |
|
| More >>
|
